LMB-2 免疫毒素
正在进行 LMB-2 免疫毒素（一种与细胞毒素结合的抗 CD25 单克隆抗体）用于复发或常规 HCL 治疗无效的患者的研究。[32]Goodman GR, Bethel KJ, Saven A. Hairy cell leukemia: an update. Curr Opin Hematol. 2003 Jul;10(4):258-66.http://www.ncbi.nlm.nih.gov/pubmed/12799530?tool=bestpractice.com[66]Gidron A, Tallman MS. Hairy cell leukemia: towards a curative strategy. Hematol Oncol Clin North Am. 2006 Oct;20(5):1153-62.http://www.ncbi.nlm.nih.gov/pubmed/16990114?tool=bestpractice.com[83]Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.http://www.ncbi.nlm.nih.gov/pubmed/10764422?tool=bestpractice.com
伊布替尼
伊布替尼（一种布鲁顿酪氨酸激酶抑制剂）目前正作为针对复发性 HCL 的单药疗法接受评估。[84]Sivina M, Kreitman RJ, Arons E, et al. The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. Br J Haematol. 2014 Jul;166(2):177-88.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104473/http://www.ncbi.nlm.nih.gov/pubmed/24697238?tool=bestpractice.com
异基因造血干细胞移植
异基因干细胞移植可能对接受过大量预治疗并且对嘌呤类似物等治疗耐药的多次复发患者起作用。[62]Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v100-7.http://annonc.oxfordjournals.org/content/26/suppl_5/v100.longhttp://www.ncbi.nlm.nih.gov/pubmed/26269205?tool=bestpractice.com
